Orchard Therapeutics Limited is a clinical stage biotechnology company with operations in the UK and in the US.
The company, incorporated in 2005 is dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases.
Our programmes are using the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders.
We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy.
Our mission is to translate results from pre-clinical and early clinical research into commercially approved therapies for patients around the world.